AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17557044 — intervention group
Group type: COMPARATOR
Intervention: Enhanced endoscopic techniques (narrow band imaging, autofluorescence imaging, confocal laser endomicroscopy)
Number of subjects: 0
Study 17557044 — intervention group
Group type: COMPARATOR
Intervention: Mainstays of treatment for advanced cancers (debulking surgery, chemotherapy, radiotherapy, palliative care)
Number of subjects: 0
Study 15148833 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 15148833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 11253158 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 768
Study 11253158 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 768
Study 11253158 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 768
Study 11253158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 11253158 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day, 400 mg/day)
Number of subjects: 768
Study 9513236 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) chemical peel at concentrations ranging from 20% to 50%; applied 48 hours before upper-eyelid blepharoplasty.
Number of subjects: 10
Study 9513236 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) chemical peel at 50% concentration; applied 48 hours before upper-eyelid blepharoplasty.
Number of subjects: 10
Study 9167210 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at 30 ng/kg/min for 48 hours
Number of subjects: 20
Study 9167210 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 2037735 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity participation
Number of subjects: 0
Study 2037735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion Model
Number of subjects: 0
Study 6953761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 62
Study 6953761 — intervention group
Group type: COMPARATOR
Intervention: Non-chemotherapy
Number of subjects: 62
Study 6953761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectics
Number of subjects: 62
Study 6953761 — intervention group
Group type: COMPARATOR
Intervention: Non-anorectics
Number of subjects: 62
Study 31023004 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-QoL-Stigma Scale
Number of subjects: 152
Study 28012804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 142
Study 28012804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 142
Study 28012804 — intervention group
Group type: COMPARATOR
Intervention: Baseline frequent cough (FC)
Number of subjects: 142
Study 28012804 — intervention group
Group type: COMPARATOR
Intervention: Cough-specific quality of life (QoL)
Number of subjects: 142
Study 25047089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 54
Study 25004186 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 252
Study 25004186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 23071528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1.3 to 1.5 mg per day for a median of 19 months)
Number of subjects: 39
Study 23071528 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 39
Study 19413178 — intervention group
Group type: EXPERIMENTAL
Intervention: GROalpha levels measured at different time points (Preop, 90 min-Xoff, 24 hours after surgery) during AAA repair
Number of subjects: 17
Study 19413178 — intervention group
Group type: COMPARATOR
Intervention: GROalpha levels in patients undergoing AAA repair
Number of subjects: 17
Study 17887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasulcular incision
Number of subjects: 184
Study 17887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Submarginal incision
Number of subjects: 184
Study 17887998 — intervention group
Group type: COMPARATOR
Intervention: Papilla base incision
Number of subjects: 184
Study 14968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg thrice daily for 5 days
Number of subjects: 24
Study 14968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg thrice daily for 5 days followed by alpha-tocopherol 200 mg thrice daily for another 5 days
Number of subjects: 24
Study 14968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 24
Study 14968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac combined with alpha-tocopherol
Number of subjects: 24
Study 11577655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational services (at least one hour)
Number of subjects: 166
Study 9196357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula (SFo)
Number of subjects: 81
Study 9196357 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chain polyunsaturated fatty acid (LC‐PUFA) enriched formula (LCPFo)
Number of subjects: 81
Study 9196357 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 81
Study 9196357 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte phosphatidylcholine and phosphatidylethanolamine (subgroup n = 20)
Number of subjects: 81
Study 9196357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis including phosphatidylcholine and phosphatidylethanolamine variables
Number of subjects: 81
Study 1531822 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 66
Study 1531822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 4003099 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Org 3770
Number of subjects: 250
Study 4003099 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Org 3770
Number of subjects: 250
Study 4003099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Org 3770
Number of subjects: 250
Study 4003099 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 250
Study 4003099 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 250
Study 30606225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative therapy (CMT) - four treatments over a 2-week period
Number of subjects: 120
Study 30606225 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control - no treatment during the 2-week period
Number of subjects: 120
Study 29861222 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques (MRT) for 15 minutes
Number of subjects: 22
Study 29861222 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects in supine position for 15 minutes without intervention)
Number of subjects: 22
Study 27133877 — intervention group
Group type: COMPARATOR
Intervention: NTHi vaccine formulations (10 or 30μg of each antigen PD and PE-PilA)
Number of subjects: 318
Study 27133877 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted formulations
Number of subjects: 318
Study 27133877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 27133877 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi vaccine formulations
Number of subjects: 318
Study 24867903 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy and exercise program
Number of subjects: 18
Study 24867903 — intervention group
Group type: COMPARATOR
Intervention: Exercise program alone
Number of subjects: 18
Study 22835512 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 127
Study 22835512 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 127
Study 22835512 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 127
Study 22835512 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of systemic antihypertensives
Number of subjects: 127
Study 22835512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ocular perfusion pressure
Number of subjects: 127
Study 20600554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoemulsion (cetylpyridinium chloride-containing)
Number of subjects: 3
Study 20600554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine gluconate
Number of subjects: 3
Study 20600554 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 3
Study 17555427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitemcinal 10 mg
Number of subjects: 392
Study 17555427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 15702239 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoyu polysaccharides (SPS) 600 mg daily
Number of subjects: 51
Study 11833398 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic training
Number of subjects: 45
Study 11833398 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwriting practice
Number of subjects: 45
Study 11833398 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study 10513175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (H, n = 24)
Number of subjects: 47
Study 10513175 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (N, n = 23)
Number of subjects: 47
Study 9395621 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-200 (7.5 g sachet mixed with water, orally)
Number of subjects: 60
Study 1715501 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (4 IU/m2 per day) for 6 months
Number of subjects: 20
Study 1715501 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 20
Study 1715501 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20
Study 6857511 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (RL, 130 mEq sodium/L, 274 mOsm/L)
Number of subjects: 58
Study 6857511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic balanced salt solution (HSL, 250 mEq sodium/L, 514 mOsm/L)
Number of subjects: 58
Study 31315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dairy product consumption (highest vs lowest quartile)
Number of subjects: 49472
Study 31315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-fat dairy product intake (highest vs lowest quartile)
Number of subjects: 49472
Study 31315238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2%-fat milk intake (higher than median vs no intake)
Number of subjects: 49472
Study 29769829 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 18
Study 29769829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 25669236 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132
Study 25669236 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (SCBT)
Number of subjects: 132
Study 24121692 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based gel applied during speculum examination
Number of subjects: 1580
Study 24121692 — intervention group
Group type: COMPARATOR
Intervention: Dry speculum (control group)
Number of subjects: 1580
Study 22502741 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of an abstract verbal stimulus
Number of subjects: 180
Study 22502741 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of the sentence
Number of subjects: 180
Study 22502741 — intervention group
Group type: COMPARATOR
Intervention: Concrete sentence condition
Number of subjects: 180
Study 22502741 — intervention group
Group type: COMPARATOR
Intervention: Abstract sentence condition
Number of subjects: 180
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus 3 days of artesunate (SP-AS3)
Number of subjects: 1365
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of amodiaquine-artesunate (AQ3-AS3)
Number of subjects: 1365
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of short-acting chlorproguanil-dapsone (CD3)
Number of subjects: 1365
Study 20368815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1365
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-AS3
Number of subjects: 1365
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ3-AS3
Number of subjects: 1365
Study 20368815 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3
Number of subjects: 1365
Study 17397731 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ SN60WF IOL
Number of subjects: 120
Study 17397731 — intervention group
Group type: COMPARATOR
Intervention: AcrySof SA60AT IOL
Number of subjects: 120
Study 17397731 — intervention group
Group type: COMPARATOR
Intervention: AcrySof Natural SN60AT IOL
Number of subjects: 120
Study 15878927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg followed by 400 microg every 3 hours)
Number of subjects: 76
Study 15878927 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg followed by 400 microg every 3 hours)
Number of subjects: 76
Study 15878927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 76
Study 15878927 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 76
Study 12208402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 long stent (GFX II stents or S670 of 24, 30, or 40 mm lengths; n = 62)
Number of subjects: 124
Study 12208402 — intervention group
Group type: COMPARATOR
Intervention: 2 short stents (GFX II or S670 stents, n = 62)
Number of subjects: 124
Study 9620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy alone (n = 71)
Number of subjects: 603
Study 9620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy in combination with anabolic steroid treatment (n = 67)
Number of subjects: 603
Study 9620907 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 603
Study 9620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 603
Study 9620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change as a time‐dependent covariate
Number of subjects: 603
Study 8077349 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 10
Study 8077349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2921681 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified oxygen
Number of subjects: 28
Study 2921681 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 28
Study 31628954 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater resection (UR)
Number of subjects: 255
Study 31628954 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection (CR)
Number of subjects: 255
Study 31182491 — intervention group
Group type: EXPERIMENTAL
Intervention: Med‐EatPlan + EVOO
Number of subjects: 3230
Study 31182491 — intervention group
Group type: EXPERIMENTAL
Intervention: Med‐EatPlan + nuts
Number of subjects: 3230
Study 31182491 — intervention group
Group type: COMPARATOR
Intervention: Control eating plan
Number of subjects: 3230
Study 27826654 — intervention group
Group type: EXPERIMENTAL
Intervention: HI (high-intensity exercise starting at 105% of the incremental peak power)
Number of subjects: 12
Study 27826654 — intervention group
Group type: EXPERIMENTAL
Intervention: I-BFR30 (intermittent BFR at 30% P peak)
Number of subjects: 12
Study 27826654 — intervention group
Group type: EXPERIMENTAL
Intervention: C-BFR30 (continuous BFR at 30% P peak)
Number of subjects: 12
Study 27826654 — intervention group
Group type: COMPARATOR
Intervention: CON30 (control exercise without BFR at 30% P peak)
Number of subjects: 12
Study 27826654 — intervention group
Group type: EXPERIMENTAL
Intervention: I-BFR0 (intermittent BFR during unloaded exercise)
Number of subjects: 12
Study 23490255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (folic acid 0.8 mg, vitamin B6 10 mg, and vitamin B12 500 μg)
Number of subjects: 8000
Study 23490255 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8000
Study 22333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal-free trivalent inactivated influenza vaccine
Number of subjects: 2116
Study 22333695 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (US-licensed influenza vaccine)
Number of subjects: 2116
Study 20374974 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT-232 (270mg)
Number of subjects: 40
Study 20374974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18535254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1078
Study 18535254 — intervention group
Group type: COMPARATOR
Intervention: Medical control
Number of subjects: 1078
Study 16075286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 16075286 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 16075286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11813149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 0
Study 11813149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy alone
Number of subjects: 0
Study 10070201 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-kHz tones with masker levels ranging from 5 to 35 dB/Hz
Number of subjects: 0
Study 10070201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-kHz tones with masker levels ranging from 5 to 35 dB/Hz
Number of subjects: 0
Study 10070201 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-msec stimuli of 0.5-kHz tones
Number of subjects: 0
Study 10070201 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-msec stimuli of 0.5-kHz tones
Number of subjects: 0
Study 9420639 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg coenzyme Q10 (CoQ10)
Number of subjects: 79
Study 9420639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 2261301 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 43
Study 2261301 — intervention group
Group type: EXPERIMENTAL
Intervention: metrizoate
Number of subjects: 43
Study 2261301 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed excretion greater than 10 min
Number of subjects: 43
Study 2261301 — intervention group
Group type: COMPARATOR
Intervention: No delayed excretion
Number of subjects: 43
Study 7396058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (375 mg, 3 times a day for 5 days)
Number of subjects: 15
Study 7396058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6‐aminopenicillanic acid)
Number of subjects: 15
Study 30901380 — intervention group
Group type: COMPARATOR
Intervention: PF‐00547659 (anti-MAdCAM-1 monoclonal antibody)
Number of subjects: 357
Study 29032705 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA app
Number of subjects: 72
Study 29032705 — intervention group
Group type: COMPARATOR
Intervention: Control patient portal (PP) app
Number of subjects: 72
Study 27240673 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 1148
Study 27240673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1148
Study 27240673 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 1148
Study 24699015 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed stress condition
Number of subjects: 0
Study 24699015 — intervention group
Group type: COMPARATOR
Intervention: Accuracy stress condition
Number of subjects: 0
Study 21899919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 278
Study 21899919 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 278
Study 20015727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray 10%
Number of subjects: 48
Study 20015727 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 2% solution
Number of subjects: 48
Study 18457617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive preventive program (quarterly examinations by general practitioner, treatment adjustments, lifestyle reinforcement)
Number of subjects: 983
Study 18457617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive preventive program
Number of subjects: 983
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD diagnoses of myofascial pain with limited opening
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD diagnoses of myofascial pain without limited opening
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD diagnoses of arthralgia
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD diagnoses of disc displacement with reduction
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: RDC/TMD diagnoses of disc displacement without reduction, osteoarthritis, and osteoarthrosis
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped diagnoses into pain versus non-pain
Number of subjects: 230
Study 16154702 — intervention group
Group type: EXPERIMENTAL
Intervention: Detecting any diagnosis versus no diagnosis
Number of subjects: 230
Study 12437643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 128
Study 12437643 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal HGF values (< 1.7 ng/ml, n = 69)
Number of subjects: 128
Study 12437643 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated HGF (≥ 1.7 ng/ml, n = 26)
Number of subjects: 128
Study 12437643 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 62)
Number of subjects: 128
Study 10599590 — intervention group
Group type: EXPERIMENTAL
Intervention: Biniwas (2 x 550 mg/day) for six months
Number of subjects: 30
Study 7861247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg every 4 months; 30 mg for infants 6-11 months)
Number of subjects: 592